These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9150702)

  • 1. Lack of relationship between 17-hydroxyprogesterone response to buserelin testing and hyperinsulinemia in polycystic ovary syndrome.
    Sahin Y; Ayata D; Keleştimur F
    Eur J Endocrinol; 1997 Apr; 136(4):410-5. PubMed ID: 9150702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.
    Pasquali R; Patton L; Pocognoli P; Cognigni GE; Gambineri A
    J Clin Endocrinol Metab; 2007 Nov; 92(11):4208-17. PubMed ID: 17785360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome.
    Unlühizarci K; Keleştimur F; Bayram F; Sahin Y; Tutuş A
    Clin Endocrinol (Oxf); 1999 Aug; 51(2):231-6. PubMed ID: 10468995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 17-Hydroxyprogesterone responses to gonadotrophin-releasing hormone agonist buserelin and adrenocorticotrophin in polycystic ovary syndrome: investigation of adrenal and ovarian cytochrome P450c17alpha dysregulation.
    Sahin Y; Keleştimur F
    Hum Reprod; 1997 May; 12(5):910-3. PubMed ID: 9194638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing.
    Ibañez L; Hall JE; Potau N; Carrascosa A; Prat N; Taylor AE
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4103-7. PubMed ID: 8923867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of hormonal response to the GnRH agonist leuprolide in brothers of women with polycystic ovary syndrome: a pilot study.
    Petermann TS; Cartes A; Maliqueo M; Vantman D; Gutiérrez C; Toloza H; Echiburú B; Recabarren SE
    Hum Reprod; 2004 Dec; 19(12):2742-7. PubMed ID: 15358722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LH pulsatility and response to a single s.c. injection of buserelin in polycystic ovary syndrome.
    Prelević GM; Würzburger MI; Balint-Peric L
    Gynecol Endocrinol; 1990 Mar; 4(1):1-13. PubMed ID: 2110712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 17-Hydroxyprogesterone response to buserelin testing in the polycystic ovary syndrome.
    Sahin Y; Keleştimur F
    Clin Endocrinol (Oxf); 1993 Aug; 39(2):151-5. PubMed ID: 8396511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adrenal androgenic response to 2-hour ACTH stimulation test in women with PCOS.
    Erel CT; Senturk LM; Oral E; Colgar U; Ertungealp E
    Gynecol Endocrinol; 1998 Aug; 12(4):223-9. PubMed ID: 9798131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens.
    Nestler JE; Jakubowicz DJ
    J Clin Endocrinol Metab; 1997 Dec; 82(12):4075-9. PubMed ID: 9398716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperinsulinemia amplifies GnRH agonist stimulated ovarian steroid secretion in women with polycystic ovary syndrome.
    Tosi F; Negri C; Perrone F; Dorizzi R; Castello R; Bonora E; Moghetti P
    J Clin Endocrinol Metab; 2012 May; 97(5):1712-9. PubMed ID: 22419715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of sequential administration of octreotide alone and octreotide/growth hormone simultaneously on buserelin stimulated ovarian steroid secretion in women with polycystic ovary syndrome.
    Piaditis GP; Hatziioanidis AH; Trovas GP; Misichronis GS; Kounadi TG; Devetzaki OA; Andronis CK; Rangou DB; Chlouverakis CS
    Clin Endocrinol (Oxf); 1996 Nov; 45(5):595-604. PubMed ID: 8977757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome.
    Nestler JE; Jakubowicz DJ
    N Engl J Med; 1996 Aug; 335(9):617-23. PubMed ID: 8687515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polycystic ovary syndrome: relationship between insulin sensitivity, sex hormone levels and ovarian stromal blood flow.
    Loverro G; Vicino M; Lorusso F; Vimercati A; Greco P; Selvaggi L
    Gynecol Endocrinol; 2001 Apr; 15(2):142-9. PubMed ID: 11379011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of polycystic ovarian changes and polycystic ovary syndrome in premenopausal women with treated type 2 diabetes mellitus.
    Kelestimur F; Unluhizarci K; Baybuga H; Atmaca H; Bayram F; Sahin Y
    Fertil Steril; 2006 Aug; 86(2):405-10. PubMed ID: 16762349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between 17-hydroxyprogesterone responses to human chorionic gonadotropin and markers of ovarian follicle morphology in women with polycystic ovary syndrome.
    Maas KH; Chuan SS; Cook-Andersen H; Su HI; Duleba A; Chang RJ
    J Clin Endocrinol Metab; 2015 Jan; 100(1):293-300. PubMed ID: 25313914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity.
    Arroyo A; Laughlin GA; Morales AJ; Yen SS
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3728-33. PubMed ID: 9360532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basal insulin-like factor 3 levels predict functional ovarian hyperandrogenism in the polycystic ovary syndrome.
    Gambineri A; Patton L; Prontera O; Fanelli F; Ciampaglia W; Cognigni GE; Pagotto U; Pasquali R
    J Endocrinol Invest; 2011 Oct; 34(9):685-91. PubMed ID: 21586896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of hyperinsulinemia in pathogenesis of polycystic ovary syndrome and treatment by reduction of insulin secretion].
    Wang A; Li M; Lu C
    Zhonghua Fu Chan Ke Za Zhi; 1998 Dec; 33(12):731-4. PubMed ID: 10806662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The utility of the gonadotrophin releasing hormone (GnRH) test in the diagnosis of polycystic ovary syndrome (PCOS).
    Lewandowski KC; Cajdler-Łuba A; Salata I; Bieńkiewicz M; Lewiński A
    Endokrynol Pol; 2011; 62(2):120-8. PubMed ID: 21528473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.